Cargando…
Human mast cells decrease SLPI levels in type II – like alveolar cell model, in vitro
BACKGROUND: Mast cells are known to accumulate at sites of inflammation and upon activation to release their granule content, e.g. histamine, cytokines and proteases. The secretory leukocyte protease inhibitor (SLPI) is produced in the respiratory mucous and plays a role in regulating the activity o...
| Autores principales: | , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2003
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC194615/ https://www.ncbi.nlm.nih.gov/pubmed/12952550 http://dx.doi.org/10.1186/1475-2867-3-14 |